-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on InflaRx, Raises Price Target to $8

Benzinga·05/11/2026 17:36:17
Listen to the news
HC Wainwright & Co. analyst Matthew Keller maintains InflaRx (NASDAQ:IFRX) with a Buy and raises the price target from $6 to $8.